Natural History of GACI With or Without ARHR2 or PXE
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03758534|
Recruitment Status : Recruiting
First Posted : November 29, 2018
Last Update Posted : November 29, 2018
|Condition or disease||Intervention/treatment|
|Generalized Arterial Calcification in Infancy Autosomal Recessive Hypophosphatemic Rickets Pseudoxanthoma Elasticum||Other: No intervention|
Generalized arterial calcification of infancy (GACI) is an ultra-rare disorder with an estimated birth prevalence of around 1 in 400,000.1 GACI is characterized by extensive arterial calcifications, arterial stenosis, myointimal proliferation and periarticular calcifications. Individuals with GACI also experience calcification in other body areas, such as joints and organs. GACI is generally fatal before birth or within the first six months after birth. The cause of death is frequently myocardial infarction or stroke. GACI is strongly associated with inactivating mutations in ectonucleotide pyrophosphate/ phosphodiesterase 1 (ENPP1); around three quarters of GACI cases investigated had one or several ENPP1 mutations. Many patients with GACI, including some without an ENPP1 mutation also present with mutations in adenosine triphosphate binding cassette transporter protein subfamily C member 6 (ABCC6). Autosomal recessive hypophosphatemic rickets type 2 (ARHR2) and pseudoxanthoma elasticum (PXE) are believed to be closely related to GACI. ARHR2 is caused by mutations in the ENPP1 gene5 and PXE is caused by mutations in the ABCC6 gene,3 with both being observed among patients with GACI. The natural history of GACI and in particular its long term morbidity and mortality are poorly understood, but a strong understanding of the condition will be crucial for further therapy development and drug testing. This study aims to address this knowledge gap.
The primary objective of this study is to characterize overall survival among patients with GACI, over time from birth.
Secondary objectives are to:
- Characterize the patient and disease characteristics;
- Describe symptomology at diagnosis and the change in symptomology over time;
- Describe treatment patterns specific to GACI or rickets
- Characterize mental/physical impairment, education, and employment situation;
- Characterize the sequelae of the disease;
- Prevalence of rickets; and
- Growth velocities.
- GACI genotype (mutation in ENPP1 and/or ABCC6) confirmed through mutational analysis of the patient and a GACI phenotype confirmed by imaging or biopsy; or
- GACI phenotype confirmed with imaging, biopsy, or mutational analysis of the parents indicating a GACI genotype (mutation in ENPP1 and/or ABCC6) coinciding with symptoms of the patient.
Data will be collected for both living and deceased patients
Retrospective multicenter chart review
|Study Type :||Observational|
|Estimated Enrollment :||80 participants|
|Official Title:||The Natural History of Generalized Arterial Calcification of Infancy (GACI) With or Without Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2) or Pseudoxanthoma Elasticum (PXE)|
|Actual Study Start Date :||March 15, 2018|
|Estimated Primary Completion Date :||December 31, 2019|
|Estimated Study Completion Date :||December 31, 2019|
- Other: No intervention
This is a retrospective chart review study.
- Survival [ Time Frame: Recruitment for this study will end in March 2019 ]This study will record the survival rate in patients with GACI
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03758534
|Contact: Frank Rutsch, MDemail@example.com|
|Contact: Kerstin Mueller, PhDfirstname.lastname@example.org|
|Münster, Germany, 48149|
|Contact: Frank Rutsch, MD +492518347700 email@example.com|
|Principal Investigator:||Frank Rutsch, MD||WWU Munster|